LeukoDx, Inc. — Form D/A
LeukoDx, Inc. of San Jose, CA, a company, filed a Form D amendment with the SEC on 2020-07-16. The offering totals $5.0M, of which $5.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2020-07-16
- Form: D/A
- Accession: 0001470820-20-000004
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $5.0M
- Amount sold: $5.0M
- Minimum investment: $5.0M
- Investors: 1
- Date of first sale: 2020-07-01
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-371131
Issuer
- Name: LeukoDx, Inc.
- CIK: 0001470820
- Entity type: Corporation
- Jurisdiction: MARYLAND
- Incorporated: 2010
- Address: 2385 Bering Drive, San Jose, CA, 95131
- Phone: 6172285729
Officers, directors & promoters (14)
| Name | Role | Location |
|---|
| Steve Hurvitz | Director | San Jose, CA |
| Nir Nimrodi | Director | Rehovot, L3 |
| Charles Piazza | Director | San Jose, CA |
| Michael Reynier | Director | Boulder, CO |
| Bruce Sholk | Director | San Jose, CA |
| Barry Zubrow | Director | San Jose, CA |
| Mark Chess | Director | Grand Rapids, MI |
| Julien Meissonnier | Director | Towson, MD |
| Julien Meissonnier | Executive Officer | Towson, MD |
| Walter Drimer | Director | Towson, MD |
| Walter Drimer | Executive Officer | Towson, MD |
| Bruce Davis | Director | Towson, MD |
| Harvey Kasdan | Director | Towson, MD |
| Marvin Slepian | Director | Towson, MD |
Other filings by this issuer (4)
More